Legend Biotech ( NASDAQ:LEGN ) Full Year 2024 Results Key Financial Results Revenue: US$627.2m (up 120% from FY 2023... Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales ...
Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...
Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...
Daiwa Securities Group Inc. lifted its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 165.5% during the fourth ...
Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...
Legend Biotech Corporation Sponsored ADR (LEGN) reported $186.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 134.7%. EPS of -$0.15 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results